Introduction
Sodium valproate (VPA) is a salt of 2-propylpentanoic acid, an anticonvulsant drug which has been in use for some three decades now. It is prescribed for the prevention of many types of partial and generalised seizure. More recently, its use has increased in other conditions such as chronic pain syndromes, the prophylaxis and treatment of migraine and some psychiatric conditions such as bipolar and schizoaffective disorders. 1 Acute VPA toxicity usually results in mild, self-limited symptoms, but occasionally can lead to life-threatening hepatic and central nervous system poisoning. Therapies to rescue such patients include ventilator and cardiovascular support and extracorporeal removal of the drug. There are also increasing reports of the use of L-carnitine in acute VPA overdose. We present a case in which this therapy was successfully used as an alternative to haemodiafiltration.
Case report
A 41-year-old female was admitted to the emergency department having reportedly taken a mixed overdose of clonazepam, oxazepam, propranolol, flupenthixol and sodium valproate. Her level of consciousness was fluctuant, but the downward trend in her Glasgow Coma Score prompted a referral to the intensive care team, who proceeded to sedate, intubate and mechanically ventilate the patient.
Following intubation, the patient exhibited increasing vasopressor requirements coupled with intermittent bradycardia. Initial laboratory assays showed a valproate level of 534 mg/L (therapeutic range 50-100 mg/L), and an ammonia level of 108 µmol/L (normal range 9-35 µmol/L), International Normalised Ratio (INR) 1.2, platelet count 105 x 10 9 /L and normal renal function. The bradycardia was treated with atropine and glucagon, the combination of which increased the heart rate into the normal range, but without improving blood pressure. Naloxone was given to treat the valproate toxicity, with no observable effect. 2 After a short period of low dose propofol, sedation was discontinued to allow neurological assessment; the pupils were equal in size and reactive to light and the patient had a normal cough reflex, but no spontaneous limb movements. Given the cocktail of drugs she had allegedly taken, it was difficult to judge how much the hyperammonaemia was responsible for her clinical state.
The UK online toxicology database (TOXBASE ® ) recommendations suggested that extracorporeal removal of sodium valproate may be appropriate for this patient, and consequently further advice was sought from the toxicology service at Guy' s and St Thomas' Hospital. In view of her ammonia level, the toxicology service recommended giving carnitine rather than initiating haemodiafiltration.
Carnitine treatment was therefore started with a loading dose of 100 mg/kg followed by doses of 15 mg/kg intravenously every four hours, resulting in a rapid fall in plasma valproate and ammonia levels. The patient was extubated the day following her admission, and although there was a brief period of intermittent agitation and disorientation there were no subsequent neurological abnormalities or other adverse overdose sequelae. The use of carnitine rather than renal replacement therapy for sodium valproate poisoning
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Valproate toxicity can be complicated by the development of hyperammonaemia, which can cause cerebral oedema and encephalopathy. We report the successful management of a case of valproate overdose using carnitine and review the metabolic pathways responsible for its therapeutic effects. 
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Discussion
Sodium valproate is usually well tolerated and exhibits fewer behavioural and cognitive side effects than many other anticonvulsants. Rarely, normal therapeutic use can lead idiosyncratically to bone marrow suppression, haemorrhagic pancreatitis, hepatotoxicity and hyperammonaemic encephalopathy. The pathophysiology of the latter two side effects is, if not fully explained, at least illuminated, by its metabolism (Figure 1) . Valproic acid is a branched-chain carboxylic acid: it resembles a fatty acid with the addition of a side chain. Most of the drug is eliminated after glucuronidation. However, about 17% is metabolised by oxidation, 30% in the endoplasmic reticulum of hepatocytes, via ωand ω1-oxidation and 70% via β-oxidation in the mitochondrion. One of the products of β-oxidation, 2-propyl-2-pentenoic acid is thought to cause cerebral oedema. 2-propyl-4-pentenoic acid, one of the cytosolic metabolites of ω-oxidation, has also been implicated in the development of hepatotoxicity and hyperammonaemia. It is noteworthy that in chronic use and overdose, the proportion of the drug metabolised by this toxin-producing route is increased. 1 The consequences of severe acute toxicity are manifold: they include central nervous system depression and agitation, myoclonus, seizures, respiratory depression, hypothermia, hypotension, electrolyte and acid-base abnormalities, hepatitis and hyperammonaemia (with normal liver function tests). Rarely, VPA overdose can lead to heart block, pancreatitis, acute renal failure, leukopaenia and thrombocytopaenia, anaemia, cerebral oedema, optic nerve atrophy and acute respiratory distress syndrome (ARDS). 3 A full discussion of the toxicity of VPA is beyond the scope also impairs this transporter. 6. Valproate metabolites combine with mitochondrial CoA-SH reducing the restoration of carnitine from acylcarnitine. Carnitine is an amino acid derivative found in plasma but active in mitochondria where it transports free fatty acids complexed with coenzyme A (and valproyl CoA) from the intermembrane space into the mitochondrial matrix for β-oxidation, a process known as the carnitine shuttle. In so doing, it also regulates levels of acyl CoA in the intermembrane space -this protects the cell from the toxic membranedestabilising effects of acyl groups and restrains their effects on metabolic enzymes. Carnitine is mainly derived from dietary sources, although about a quarter of the body' s requirement is synthesised from methionine and lysine in the liver and kidneys. Reduced carnitine levels therefore result in reduced ATP synthesis and accumulation of acyl CoA in the mitochondrion, leading to decreased gluconeogenesis and decreased ketoacid oxidation. Carnitine deficiency also impairs the metabolism of ammonia, either via deficient synthesis of nacetyl glutamic acid, a co-factor for carbamoyl phosphate synthase, the enzyme responsible for introducing nitrogen into the urea cycle or by directly inhibiting the enzyme. 1 Reduced fatty acid oxidation in the face of unchanged metabolic demand probably also increases amino acid catabolism for energy production, creating an increase in nitrogenous waste. Putting the brakes on β-oxidation of valproic acid itself also shifts metabolism to the cytosolic route, leading to increased production of toxic ω-oxidation metabolites. In addition to their direct effects on hepatocytes and astrocytes (see above), they further impair carbamoyl phosphate synthase. Sodium valproate also increases renal production of ammonia by enhancing glutamine uptake in tubular cells, exacerbating the problem. 1 Valproate causes encephalopathy, usually but not always because of hyperammonaemia. 4 About 50% of patients taking valproate have raised ammonia levels. 1 However, only a small proportion present with hyperammonaemic encephalopathy. They have decreased levels of consciousness, focal neurological symptoms and impaired seizure control. Whereas there does not appear to be much correlation between ammonia levels and the clinical picture, they do correlate directly with valproate assay results and inversely with plasma carnitine. Patients with existing urea cycle impairment or carnitine deficiency are at higher risk as are those concurrently taking phenobarbital, phenytoin or carbamazepine. 3 Carnitine deficiency can be acquired secondary to catabolic states, liver, heart and renal failure, malabsorption syndromes, Fanconi syndrome, diabetes mellitus, Alzheimer' s disease and drugs other than valproate such as pivalic acid-containing antibiotics eg pivmecillinam and some chemotherapeutic agents (cisplatin, doxorubicin and ifosfamide). 1 In normal conditions, astrocytes and adjacent neurones have a symbiotic relationship. Astrocytes provide neurones with ATP, glutamine and cholesterol. Neurones then metabolise glutamine to glutamate, the excitatory neurotransmitter. After glutamate is released into the synapse by a neurone, it is reabsorbed by an astrocyte and metabolised back to glutamine. 5 The metabolic adaptation to hyperammonaemia includes reduced production and increased excretion by the kidney, as well as increased metabolism of ammonia to glutamine by muscle and brain tissue. Acute changes may increase intracellular osmolarity in astrocytes leading in turn to cell swelling and loss; inflammatory cytokines such as tumour necrosis factor-α, interleukin-1, interleukin-6 and interferon are also produced. Ammonia inhibits the Kreb' s cycle in surviving astrocytes; together with falling levels of reduced nicotinamide adenine dinucleotide, this favours the production of lactate from pyruvate. In addition, reduced glutamate receptor expression on astrocytes increases the synaptic concentration of this neurotransmitter, potentially triggering seizures. Local cerebral autoregulation is lost and cerebral blood flow increased. The result of all these processes is the potential for the development of cerebral oedema, intracranial hypertension and the clinical picture of hyperammonaemic encephalopathy. 5 Chronic hyperammonaemia produces encephalopathy less often because the body adapts to slow changes in ammonia levels: the osmolar shifts are counteracted, muscle and splanchnic metabolism of ammonia is increased, renal production is decreased and excretion increased, NMDA receptor expression is down-regulated and ammonia produces more of an inhibitory effect via GABA receptors. 5 Exogenous carnitine supplementation is thought to decrease ammonia levels by binding VPA, restoring β-oxidation to its normal function, increasing the production of acyl-CoA and relieving the inhibition of the urea cycle. 1 Carnitine is more familiar to neonatologists, who use it for the treatment of deficiency due to inborn errors of metabolism and prematurity. There is evidence of effective supplementation in chronic VPA users with hyperammonaemia and hypocarnitinaemia with resolution of both markers; however, the clinical condition was found not always to correlate with the ammonia concentration. 6 In the acute setting, carnitine appears to normalise VPA metabolism, with a reversion from ω-oxidation to β-oxidation. Carnitine supplementation for acute hyperammonaemia secondary to therapeutic VPA initiation has also led to rapid correction of ammonia levels; again, the encephalopathy does not always respond in tandem, suggesting other causes for it in certain cases. Carnitine has been shown, in a retrospective study, to reduce mortality in severe VPAinduced hepatotoxicity. 7 All this evidence is limited to case reports and small series. Encouragingly, a review of 674 patients with acute VPA ingestion in which 251 doses of carnitine were administered did not show any evidence of side effects from its administration. 8
Case reports
Conclusion
Acute valproate poisoning is an ever present problem for intensive care physicians which is likely, if anything, to increase in magnitude as new uses are found for the drug. Carnitine supplementation has been recommended for patients with hyperammonaemia, lethargy/coma and hepatic dysfunction and appears to be safe. As illustrated by this case, it can also be very effective, obviating the need for more invasive and higher risk therapies. Our case also highlights the benefit that can be gained from talking to an expert about an individual case rather than relying solely on generic guidance from a database.
